Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies
D Sermer, C Batlevi, ML Palomba, G Shah… - Blood …, 2020 - ashpublications.org
The prognosis of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma
(DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R …
(DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R …
[HTML][HTML] Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed/refractory diffuse large B cell lymphoma
MS Hoffmann, BD Hunter, PW Cobb, JC Varela… - … and Cellular Therapy, 2023 - Elsevier
Diffuse large B cell lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin
lymphoma. Although outcomes to frontline therapy are encouraging, patients who are …
lymphoma. Although outcomes to frontline therapy are encouraging, patients who are …
Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma
M Ernst, A Oeser, B Besiroglu… - Cochrane Database …, 2021 - cochranelibrary.com
Background Diffuse large B‐cell lymphoma (DLBCL) is an aggressive cancer of the
lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10 …
lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10 …
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
CD19 chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough for patients
with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), inducing sustained …
with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), inducing sustained …
[HTML][HTML] Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma: a multicenter analysis
Chimeric antigen receptor T cell (CAR-T) therapy is approved for treatment of
relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). Here we evaluate whether …
relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). Here we evaluate whether …
CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?
J Westin, LH Sehn - Blood, The Journal of the American Society …, 2022 - ashpublications.org
The standard of care treatment strategy for patients with relapsed or refractory large B-cell
lymphoma (LBCL) has been high-dose chemotherapy followed by autologous stem cell …
lymphoma (LBCL) has been high-dose chemotherapy followed by autologous stem cell …
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission
M Shadman, M Pasquini, KW Ahn… - Blood, The Journal …, 2022 - ashpublications.org
The relative efficacy of autologous hematopoietic cell transplant (auto-HCT) vs chimeric
antigen receptor T-cell (CAR-T) therapy in patients with diffuse large B-cell lymphoma …
antigen receptor T-cell (CAR-T) therapy in patients with diffuse large B-cell lymphoma …
A review of two regulatory approved anti-CD19 CAR T-cell therapies in diffuse large B-cell lymphoma: why are indirect treatment comparisons not feasible?
J Zhang, J Li, Q Ma, H Yang, J Signorovitch, E Wu - Advances in Therapy, 2020 - Springer
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapies can be effective for diffuse large
B-cell lymphoma (DLBCL), a cancer with limited treatment options and poor outcomes …
B-cell lymphoma (DLBCL), a cancer with limited treatment options and poor outcomes …
Outcomes of relapsed/refractory diffuse large B‐cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population …
S Harrysson, S Eloranta, S Ekberg… - British Journal of …, 2022 - Wiley Online Library
Several recently published trials investigate novel therapies for relapsed/refractory diffuse
large B‐cell lymphoma (R/R DLBCL). To estimate the benefit of these therapies in the real …
large B‐cell lymphoma (R/R DLBCL). To estimate the benefit of these therapies in the real …
Modern management of relapsed and refractory aggressive B-cell lymphoma: a perspective on the current treatment landscape and patient selection for CAR T-cell …
V Bachanova, MA Perales, JS Abramson - Blood Reviews, 2020 - Elsevier
Approximately 65% of patients with diffuse large B-cell lymphoma are cured with first-line
therapy. However, approximately 10% to 15% exhibit primary refractory disease, and 20% to …
therapy. However, approximately 10% to 15% exhibit primary refractory disease, and 20% to …